98%
921
2 minutes
20
Immediate drug hypersensitivity reactions (IDHRs) pose significant diagnostic challenges, often requiring potentially hazardous drug challenge testing (DCT). Flow cytometry-based cellular tests including the basophil activation test (BAT), the mast cell activation test (MAT) and the T cell activation test (TAT) offer promising alternatives to reduce DCT reliance. While these tests are still in development, they demonstrate potential to compete with skin tests by providing superior diagnostic performance and improved patient safety by reducing the need for DCT. Furthermore, it is encouraging that these flow cytometry-based tests are also suitable for challenging populations, such as children. Despite requiring specialised infrastructure, these tests have the potential to be cost-effective when performed in reference centres and may offer unique mechanistic insights into immediate drug hypersensitivity reactions. However, further research is needed to validate their reliability, address pharmaceutical-specific testing considerations, and potentially integrate them into clinical guidelines.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/all.16548 | DOI Listing |
Support Care Cancer
September 2025
Methodist Le Bonheur Healthcare, Department of Pharmacy, Memphis, TN, USA.
Purpose: Hypersensitivity reactions are a side effect of bleomycin. Test doses have been utilized to attempt to predict patients who would develop these reactions. Despite this, there is scant data available on whether these test doses actually predict the development of reactions.
View Article and Find Full Text PDFAm J Dermatopathol
September 2025
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Background: Dermatologic adverse events (dAEs) are prevalent with BCR-ABL tyrosine kinase inhibitors (TKIs), affecting quality of life and treatment adherence. Despite their prevalence, underlying mechanisms of toxicity remain unclear. We sought to characterize dAEs across TKI generations to elucidate mechanisms driving toxicities.
View Article and Find Full Text PDFJ Oncol Pharm Pract
September 2025
Department of Toxicology, Showa Medical University Graduate School of Pharmacy, Tokyo, Japan.
IntroductionOxaliplatin is a platinum-based drug widely used for treating colorectal cancer. However, its use is often complicated by hypersensitivity reactions and other adverse effects, including peripheral neuropathy and myelosuppression. We evaluated the efficacy of prophylactic hydrocortisone administration in preventing hypersensitivity reactions during oxaliplatin therapy in patients with colorectal cancer.
View Article and Find Full Text PDFCureus
August 2025
Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Graduate School of Medicine, Mie University, Tsu, JPN.
Conversion surgery is increasingly used for initially unresectable esophageal cancer patients responding to induction therapy. The integration of immune checkpoint inhibitors (ICIs) into standard chemotherapy regimens is expected to increase the number of patients undergoing this approach. However, ICIs can cause immune-related adverse events (irAEs), which are often difficult to diagnose in the postoperative setting.
View Article and Find Full Text PDFBull Cancer
September 2025
Department of Pathology and Medical Biology, Cancer Genetics Laboratory, Gustave Roussy, Villejuif, France.
The effectiveness and tolerability of medicines can vary considerably from person to person, even at the same dose. This variation is influenced by many factors, including constitutional genetic characteristics. In fact, some people have genetic variations that are common and neutral in the population, known as polymorphisms, which can affect drug metabolism or make them more susceptible to certain adverse effects.
View Article and Find Full Text PDF